Skip to main content

Table 2 Polymorphisms in lipid metabolizing genes and risk of CKD

From: Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - cross-sectional data from the J-MICC study

Polymorphism

Genotype

CKD (+)

CKD (-)

Per allele

P

  

(n = 564)

(n = 2,704)

aOR (95% CI)*

 

APOA1 Ala61Thr (G219A)

G/G

506 (89.7%)

2,423 (89.6%)

  

(rs12718465)

A/G

56 (9.9%)

268 (9.9%)

0.98 (0.74-1.31)

0.901

 

A/A

2 (0.4%)

13 (0.5%)

  

APOA5 G553T (Cys185Gly)

G/G

483 (85.6%)

2,375 (87.8%)

  

(rs2075291)

G/T

79 (14.0%)

309 (11.4%)

1.12 (0.87-1.43)

0.378

 

T/T

2 (0.4%)

20 (0.7%)

  

APOA5 T-1131C

T/T

221 (39.2%)

1,197 (44.3%)

  

(rs662799)

C/T

258 (45.7%)

1,183 (43.8%)

1.22 (1.06-1.39)

0.004

 

C/C

85 (15.1%)

324 (12.0%)

  

APOA5 C/A

C/C

210 (37.2%)

1,028 (38.0%)

  

(rs6589567)

C/A

264 (46.8%)

1,241 (45.9%)

1.03 (0.90-1.17)

0.684

 

A/A

90 (16.0%)

435 (16.1%)

  

APOA5 T1259C

T/T

282 (50.0%)

1,437 (53.1%)

  

(rs2266788)

T/C

224 (39.7%)

1,059 (39.2%)

1.19 (1.03-1.37)

0.019

 

C/C

58 (10.3%)

208 (7.7%)

  

APOB A/G

A/A

308 (54.6%)

1,421 (52.6%)

  

(rs673548)

A/G

210 (37.2%)

1,056 (39.1%)

0.95 (0.82-1.10)

0.490

 

G/G

46 (8.2%)

227 (8.4%)

  

APOE Arg158Cys (C609T)

C/C

523 (92.7%)

2,472 (91.4%)

  

(rs7412)

C/T

40 (7.1%)

226 (8.4%)

0.82 (0.58-1.15)

0.255

 

T/T

1 (0.2%)

6 (0.2%)

  

APOE Cys112Arg (T471C)

T/T

469 (83.2%)

2,200 (81.4%)

  

(rs429358)

T/C

88 (15.6%)

466 (17.2%)

0.91 (0.73-1.13)

0.388

 

C/C

7 (1.2%)

38 (1.4%)

  

APOE T-219G

T/T

290 (51.4%)

1,317 (48.7%)

  

(rs405509)

T/G

228 (40.4%)

1,090 (40.3%)

0.90 (0.78-1.03)

0.124

 

G/G

46 (8.2%)

297 (11.0%)

  

APOE cluster A/G

A/A

452 (80.1%)

2,155 (79.7%)

  

(rs4420638)

A/G

104 (18.4%)

509 (18.8%)

0.97 (0.79-1.20)

0.798

 

G/G

8 (1.4%)

40 (1.5%)

  

TOMM40 A/G

A/A

118 (20.9%)

825 (30.5%)

  

(rs157580)

A/G

299 (53.0%)

1,257 (46.5%)

1.27 (1.12-1.45)

<0.001

 

G/G

147 (26.1%)

622 (23.0%)

  

HMGCR G/A

G/G

163 (28.9%)

736 (27.2%)

  

(rs3846662)

G/A

278 (49.3%)

1,326 (49.0%)

0.91 (0.80-1.04)

0.162

 

A/A

123 (21.8%)

642 (23.7%)

  

LPL G/A

G/G

366 (64.9%)

1,797 (66.5%)

  

(rs331)

G/A

177 (31.4%)

816 (30.2%)

1.04 (0.88-1.22)

0.681

 

A/A

21 (3.7%)

91 (3.4%)

  

LPL G1791C (Ser474Stop)

G/G

423 (75.0%)

2,083 (77.0%)

  

(rs328)

G/C

131 (23.2%)

579 (21.4%)

1.07 (0.89-1.30)

0.466

 

C/C

10 (1.8%)

42 (1.6%)

  

NR1H3 G/A

G/G

301 (53.4%)

1,512 (55.9%)

  

(rs7120118)

G/A

224 (39.7%)

1,027 (38.0%)

1.12 (0.97-1.31)

0.125

 

A/A

39 (6.9%)

165 (6.1%)

  

NR1H3 A/G

A/A

299 (53.0%)

1,524 (56.4%)

  

(rs2167079)

A/G

227 (40.2%)

1,017 (37.6%)

1.14 (0.99-1.33)

0.078

 

G/G

38 (6.7%)

163 (6.0%)

  

MTNR1B A/G

A/A

250 (44.3%)

1,245 (46.0%)

  

(rs1447352)

A/G

247 (43.8%)

1,176 (43.5%)

1.06 (0.92-1.22)

0.392

 

G/G

67 (11.9%)

283 (10.5%)

  

FADS2 C/T

C/C

227 (40.2%)

979 (36.2%)

  

(rs174570)

C/T

250 (44.3%)

1,266 (46.8%)

0.91 (0.80-1.04)

0.167

 

T/T

87 (15.4%)

459 (17.0%)

  

KCNJ11 A1577G (Ile337Val)

A/A

240 (42.6%)

1,068 (39.5%)

  

(rs5215)

A/G

241 (42.7%)

1,274 (47.1%)

0.95 (0.83-1.09)

0.485

 

G/G

83 (14.7%)

362 (13.4%)

  

TMEM57 A/G

A/A

256 (45.4%)

1,186 (43.9%)

  

(rs10903129)

A/G

254 (45.0%)

1,234 (45.6%)

0.90 (0.78-1.04)

0.168

 

G/G

54 (9.6%)

284 (10.5%)

  

DOCK7 A/C

A/A

347 (61.5%)

1,542 (57.0%)

  

(rs1167998)

A/C

188 (33.3%)

996 (36.8%)

0.86 (0.74-1.01)

0.061

 

C/C

29 (5.1%)

166 (6.1%)

  

CELSR2 C/T

C/C

516 (91.5%)

2,413 (89.2%)

  

(rs4970834)

C/T

46 (8.2%)

280 (10.4%)

0.79 (0.58-1.07)

0.133

 

T/T

2 (0.4%)

11 (0.4%)

  

LIPC Val95Met (G340A)

G/G

342 (60.6%)

1,616 (59.8%)

  

(rs6078)

G/A

193 (34.2%)

945 (34.9%)

0.96 (0.82-1.13)

0.643

 

A/A

29 (5.1%)

143 (5.3%)

  

LIPC T-514C

T/T

132 (23.4%)

731 (27.0%)

  

(rs1800588)

T/C

290 (51.4%)

1,353 (50.0%)

1.10 (0.97-1.26)

0.143

 

C/C

142 (25.2%)

620 (22.9%)

  

CETP TaqIB (G > A)

G/G

234 (41.5%)

934 (34.5%)

  

(rs708272)

G/A

251 (44.5%)

1,315 (48.6%)

0.81 (0.71-0.92)

0.002

 

A/A

79 (14.0%)

455 (16.8%)

  

CETP G/T

G/G

372 (66.0%)

1,692 (62.6%)

  

(rs3764261)

G/T

170 (30.1%)

872 (32.2%)

0.86 (0.73-1.01)

0.068

 

T/T

22 (3.9%)

140 (5.2%)

  

CETP Ile405Val (G > A)

G/G

147 (26.1%)

753 (27.8%)

  

(rs5882)

G/A

277 (49.1%)

1,312 (48.5%)

1.06 (0.93-1.20)

0.403

 

A/A

140 (24.8%)

639 (23.6%)

  

CETP A-629C

A/A

162 (28.7%)

825 (30.5%)

  

(rs1800775)

A/C

279 (49.5%)

1,366 (50.5%)

1.10 (0.96-1.25)

0.174

 

C/C

123 (21.8%)

513 (19.0%)

  
  1. *aOR: adjusted odds ratio (adjusted for age and sex); 95% CI: 95% confidence interval; CKD: chronic kidney disease.